Efficacy of Adefovirdipivoxilin Therapy for Patients with Chronic Hepatitis B Resistant to Lamivudine

Objective To observe the efficacy and safety of adefovirdipivoxilin therapy for patients with chronic hepatitis B resistant to lamivudine.Methods Randomized,doubleblind,lamivudine controlled study was conducted in 86 chronic hepatitis B patients.Eligible patients stopped lamivudine therapy and were randomly assigned to respectively receive oral 10mg of adefovirdipivoxil once daily and oral 100mg of lamivudine once daily for 6 months.Serum HBV DNA,hepatitis B serology markers and ALT level were measured at regular intervals,the adverse events were recorded at the same time.Results After 3-month treatment,the responding rates of serum HBV DNA were 65.1% (28 cases) in adefovirdipivoxil group and 30.2%(13 cases) in lamivudine group (χ2=10.488,P=0.002).And after 6-month treatment,the responding rates of serum HBV DNA were 88.4%(38 cases) in adefovirdipivoxil group and 51.2%(22 cases) in lamivudine group (χ2=14.113,P=0.000),but no statistical significance was found in HBeAg sero conversion rate between the two groups (P=0.192).Conclusion Adefovirdipivoxil was safe and efficative for lamivudine-resistant patients with chronic hepatitis B.